Emergent BioSolutions awarded $30M contract modification for CYFENDUS

Emergent BioSolutions (EBS) announced it has received a $30M contract modification from the Biomedical Advanced Research and Development Authority, BARDA, part of the Administration for Strategic Preparedness and Response, ASPR, within the U.S. Department of Health and Human Services, HHS, to supply CYFENDUS. Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026. “This new contract modification is the next step in our ongoing engagement with the U.S. government, with the shared goal to help ensure medical countermeasures, like CYFENDUS vaccine, are readily available to safeguard civilian populations against the potential threat of anthrax,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “We’re proud to leverage a U.S.-based supply chain for our anthrax vaccines, as we believe this is critical to Emergent’s leadership and continued support of the U.S. government’s national security priorities.”